Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + trastuzumab with sequential capecitabine in HER2-positive recurrent or metastatic breast cancer after early relapse following adjuvant trastuzumab
2008-007495-20Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, trastuzumab and capecitabine in breast cancer, sponsored by Roche. Primary endpoint: Progression-free survival following second-line therapy. Started Feb 2009; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-007495-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007495-20.